Skip to main content
Home

Search form

  • ABOUT US
    • ECFS Society Details
      • Society Information
      • Applications for Support
    • ECFS Membership
      • Membership Subscription
      • Membership Demographics
    • Other Information
      • Latest News
      • Job Opportunities
      • Grants and Programmes
      • Links
  • RESEARCH
    • ECFS Projects
      • ECFS Clinical Trials Network
      • ECFS Patient Registry
    • ECFS Working Groups
      • Diagnostic Network
      • Exercise
      • Neonatal Screening
      • Fungal Pathogens
      • Pulmonary Exacerbation
    • Special Projects
      • ECFS / CF Europe Post-Doctoral Research Fellowship
      • CFQ-R questionnaire and CF candidates for lung transplant
      • EU funded projects
      • MucoFong International Project
      • Complete CFTR gene mutation analysis in European patients with Cystic Fibrosis
    • Past Working Groups
      • Cystic Fibrosis Molecular and Cell Biology and Physiology Basic Science
      • ECFS Gene Modifier Working Group
      • ECFS Non Tuberculous Mycobacteria Working Group
  • CARE
    • ECFS Standards Of Care
    • ECFS Working Groups
      • Exercise
      • Diagnostic Network
      • Neonatal Screening
      • Mental Health
      • Fungal Pathogens
      • Pulmonary Exacerbation
      • Telehealth
    • Allied Health Professionals
      • ECFS Nursing Special interest Group
      • European CF Pharmacy Group
      • European Cystic Fibrosis Nutrition Group
      • European Psychosocial Special Interest Group
      • ECFS Physiotherapy Special Interest International Group
  • EDUCATION
  • CONFERENCES & EVENTS
    • European Cystic Fibrosis Conference
    • ECFS Basic Science Conference
    • Related events
    • Past ECFS conferences
  • PUBLICATIONS
    • About Publications
      • The Journal of Cystic Fibrosis
      • ECFS Newsletter
      • ECFS Book
      • ERS Monograph
    • Resources
      • Search All Resources
      • CF Research News
      • Consensus Reports
      • ECFS Guidelines
      • Free Access Articles
      • CF Literature
  • MEMBERSHIP
  • LOG IN

Care of patients with CF

Anti-inflammatory Treatment for Exacerbations in Cystic Fibrosis

  • Read more about Anti-inflammatory Treatment for Exacerbations in Cystic Fibrosis

Response to oral antibiotic treatment in people with cystic fibrosis

  • Read more about Response to oral antibiotic treatment in people with cystic fibrosis

Ivacaftor impacts nutrition and growth status in 4 to 24 month old children within the first 12 weeks

  • Read more about Ivacaftor impacts nutrition and growth status in 4 to 24 month old children within the first 12 weeks

Year in Review (2022): Modulators and COVID-19: the story does on

  • Read more about Year in Review (2022): Modulators and COVID-19: the story does on

Successful treatment of a blockage in the lower portion of the small intestine in patients with cystic fibrosis using a solution administered during a colonoscopy.

  • Read more about Successful treatment of a blockage in the lower portion of the small intestine in patients with cystic fibrosis using a solution administered during a colonoscopy.

Anxiety and Depression Symptom Patterns over 6 years in one Pediatric CF Center

  • Read more about Anxiety and Depression Symptom Patterns over 6 years in one Pediatric CF Center

Weight A Minute: Exploring the effect on total weight, fat and fat-free weight after the initiation of Elexacaftor/ Tezacaftor/ Ivacaftor in adults with CF

  • Read more about Weight A Minute: Exploring the effect on total weight, fat and fat-free weight after the initiation of Elexacaftor/ Tezacaftor/ Ivacaftor in adults with CF

People with CF face high costs of CF care which have implications for debt, access to health care, adequate food, and other necessities of life.

  • Read more about People with CF face high costs of CF care which have implications for debt, access to health care, adequate food, and other necessities of life.

What happens to muscle, fat and body mass index between 8 and 18 years of age in children with cystic fibrosis

  • Read more about What happens to muscle, fat and body mass index between 8 and 18 years of age in children with cystic fibrosis

Elexacaftor/Tezacaftor/Ivacaftor improves CFTR activity and pulmonary function in Cystic Fibrosis Patients carrying the N1303K Mutation

  • Read more about Elexacaftor/Tezacaftor/Ivacaftor improves CFTR activity and pulmonary function in Cystic Fibrosis Patients carrying the N1303K Mutation
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next
  • last
Terms & Conditions Privacy policy  Accessibility Sitemap Contact 
© EUROPEAN CYSTIC FIBROSIS SOCIETY 2025. All rights reserved. Website by VidaVia (link is external)
European Cystic Fibrosis Society (ECFS)